Ares Genetics, a Curetis Group Company, Joins NVIDIA Inception and AWS Activate Programs
- Ares Genetics selected for NVIDIA and AWS programs to accelerate commercialization of its AI-powered Universal Pathogenome Assay – ARESupa
- NVIDIA Inception program accelerates start-ups that revolutionize industries with advancements in AI
Vienna, Austria, and Holzgerlingen, Germany, December 10, 2019, 08:00 am CET - Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that its fully-owned subsidiary Ares Genetics has joined the NVIDIA Inception program as a community member. The Inception program is designed to nurture start-ups revolutionizing industries with advancements in AI and data sciences. This virtual accelerator offers go-to-market support, expertise, and technology for program members through deep learning training, exclusive Inception events, and GPU discounts.
The Company further announced that it has been selected for the AWS Activate program, under which Amazon Web Services (AWS) provides portfolio start-ups with the resources they need to quickly start and scale their digital businesses on AWS. Under the AWS Activate program, Ares Genetics will receive cloud computing credits, training, and support to accelerate development and commercialization of its AI-powered ARESupa.
NVIDIA is partnering with AWS to provide leading-edge infrastructure to start-ups so they can innovate and grow. Members of either company’s start-up program — NVIDIA Inception or AWS Activate — are eligible to receive benefits provided by the other.
Ares Genetics is a digital diagnostics company utilizing AI-powered molecular diagnostics to advance the field of infectious disease testing. The Company has recently launched the ARESupa - Universal Pathogenome Assay, an award-winning tool for personalized antibiotic susceptibility prediction combining next-generation sequencing with AI. ARESupa is based on whole-genome sequencing of bacterial strains isolated from clinical specimens, combined with data analysis and interpretation powered by ARESdb, Ares Genetics’ unique, proprietary reference database on genetic antimicrobial resistance markers. ARESdb covers genomes of about 40,000 bacterial strains and associated susceptibility data for more than 100 different antibiotics. Currently under development is an ARESupa laboratory-developed test on native patient samples for human diagnostic use in indications in which current culture-based diagnostic practice is inherently challenging. Additionally, the Company has teamed up with Sandoz and launched a pharma partnering program in December 2018 to support drug development and life cycle management via a digital anti-infectives platform combining established microbiology laboratory methods with advanced bioinformatics and AI methods.
"We are proud that the further development and commercialization of our AI-powered solutions for infectious disease diagnostics and therapeutics will be supported by two of the world’s leading companies in AI, data-driven solutions, and cloud computing," commented Dr. Andreas Posch, Managing Director and CEO of Ares Genetics. "Already today, we support various leading customers in the healthcare and pharma industry with our ARESupa test and are currently working on globally scaling our business via our cloud-based interpretation platform."
###
About ARESupa Universal Pathogenome Assay
Information on antibiotic susceptibility of pathogens is of utmost importance for clinical practice, epidemiology and public health purposes as well as for the development of pharmaceutical products in the infectious disease sector. Ares Genetics therefore has developed a molecular Antibiotic Susceptibility Test (AST) that is marketed under the brand name ARESupa – Universal Pathogenome Assay and is capable of accurately identifying microbial pathogens as well as predicting antibiotic susceptibility via artificial intelligence-powered interpretation of high-throughput DNA sequencing data obtained by next-generation sequencing technologies.
ARESupa is based on whole-genome sequencing of bacterial strains isolated from clinical specimens, combined with data analysis and interpretation powered by ARESdb, Ares Genetics’ unique, proprietary reference database on genetic antimicrobial resistance markers. ARESdb covers genomes of about 40,000 bacterial strains and associated susceptibility data for more than 100 different antibiotics.
ARESupa already today performs in line with FDA requirements for over 50 drug/pathogen combinations with prediction algorithms for further drug/pathogen combinations in development.
The test is initially offered for non-diagnostic applications in epidemiology, infection control, and outbreak analysis for customers in the public health sector and the pharmaceutical industry. A laboratory-developed test (LDT) on native patient samples for human diagnostic use in indications in which current culture-based diagnostic practice is inherently challenging is planned. Furthermore, Ares Genetics has recently entered into a multi-phase strategic partnership with an undisclosed leading global in vitro diagnostics corporation to jointly develop diagnostic solutions for infectious disease testing based on the ARESupa.
For further information and quotes, please register on the Ares Genetics cloud platform:
or contact
Ares Genetics GmbH
Karl-Farkas-Gasse 18
A-1030 Wien
Austria
Email: services@ares-genetics.com
About Curetis and Ares Genetics
Curetis N.V.’s (Euronext: CURE) goal is to become a leading provider of innovative solutions for molecular microbiology diagnostics designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients.
Curetis’ Unyvero System is a versatile, fast and highly automated molecular diagnostic platform for easy-to-use, cartridge-based solutions for the comprehensive and rapid detection of pathogens and antimicrobial resistance markers in a range of severe infectious disease indications. Results are available within hours, a process that can take days or even weeks if performed with standard diagnostic procedures, thereby facilitating improved patient outcomes, stringent antibiotic stewardship and health-economic benefits. Unyvero in vitro diagnostic (IVD) products are marketed in Europe, the Middle East, Asia and the U.S.
Curetis’ wholly owned subsidiary Ares Genetics GmbH is developing next-generation solutions for infectious disease diagnostics and therapeutics. The ARES Technology Platform combines the presumably most comprehensive database worldwide on the genetics of antimicrobial resistances, ARESdb, with advanced bioinformatics and artificial intelligence.
For further information, please visit www.curetis.com and www.ares-genetics.com.
Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This press release includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis’ actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Contact Details
Curetis GmbH
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr@curetis.com or ir@curetis.com
www.curetis.com
Curetis International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68